Overall Survival
The follow-up was completed in 82% of cases and the period ranged from 1 to 172 months (127±34 months) and from 0,5 to 173 months (117±43 months) for the SAC and DAC groups, respectively. In the SAC group, a total of 101 patients were included in the follow up analysis. Among them, 31(27,9%) died: 14/31(45%) for a cardiac cause, 2/31(6.4%) for respiratory insufficiency, 8/31(25.8%) for extracardiac cause and in the remaining 7 cases (22,6%) the cause of death remained unknown because of a non-retrievable information.
In the DAC group (104 patients), 29(27,9%) died: 6/29(20,7%) for a cardiac cause, 3/29(10,3%) for extracardiac cause, 20/29(68,9%) the cause of death remained unknown.
The all-cause mortality Kaplan-Meier estimates show 81% and 73% of survival, for DAC and SAC respectively, at a median follow-up of 11 years(Fig.1.A).